1/
My top trials, AHA 2022
1. TRANSFORM-HF: torsemide vs furosemide in hosp. HF
2. RESPECT EPA: EPA 1.8g/d + statin vs statin alone in stable CAD
3. ISCHEMIA-EXTENDed: interim mortality analysis of ISCHEMIA & ISCHEMIA-CKD at longer f/u
4. EMPA-KIDNEY: empagliflozin vs pbo in CKD

The new CHFS board and President Justin Ezekowitz ! Celebrated last night with our trainee 🏆 winners and Annual Achievement award to Serge Lepage. Congrats anique ducharme on an incredible 2 yrs as Pres. #CCCongress CCS

Top3 heart failure trials in October 2022: #CardioTwitter

🥇Managing HF in patients on dialysis Journal of Cardiac Failure

🥈 Hydrochlorothiazide vs chlorthalidone, what is the difference? Circulation

🥉HF drug treatment ➡️Inertia, y itration, and discontinuation: EVOLUTION HF JACC Journals

Initiation and titration references for in-patients with transition to out-patient care

Steve Greene European Society of Cardiology Journals JACC Journals Medscape Nurses Jae Patton, CRNP, AACC Kate Morgan MSN, ACNP-BC, CHFN, AACC Adam Burget Andrea Price, RCIS, CPHQ, AACC Derek Pineda

In an analysis of the Get With the Guidelines-AFIB registry, researchers found that Black patients with atrial fibrillation were less likely to receive anticoagulant therapy at discharge and experienced higher rates of adverse outcomes at 1-year. ja.ma/3ziwJrQ

The decongestive effect of EMPA in acute heart failure. All measured metrics of decongestion (weight, weight adjusted for diuretics, hematoctite change and congestion score) were better in EMPA arm. academic.oup.com/eurheartj/adva…

The effect of EMPA on weight in AHF patients

Lauren Gray Gilstrap, MD, MPH (Lauren Gilstrap), an advanced heart disease and cardiac transplant physician and researcher, has died at age 38.

Her colleagues remember her as 'a force to behold,' 'a dynamo, a firecracker,' and a 'consummate clinician.'

tctmd.com/news/lauren-gr…

Terrific new paper lead by Utibe R. Essien, MD MPH

AHA Science AHA Research #GWTG
Clyde Yancy, MD, MSc

Association of Race and Ethnicity With Oral Anticoagulation and Outcomes in Atrial Fibrillation ja.ma/3TZBUVv via JAMA Cardiology part of JAMA Network

Saw a patient in follow up today.

HFrEF, NYHA class 2 symptoms

Coreg 50 bid
Sac/Val 97/103
Eplerenone
Empagliflozin

He’s in the 1% on target #GDMTWorks

Offered him ivabridine for bonus credit.

Great to see patients doing well on Rx!

Congratulations Harriette Van Spall, MD MPH for you Nanette K. Wenger Research Goes Red® Award newsroom.heart.org/news/drs-harri… your PACT- HF trial utilised novel trial methologies ahead of its time, and you are a global ambassador for collaborative working in heart failure PHRI | Population Health Research Institute 🇨🇦

In patients with #HFpEF or #HFmrEF , the benefit of #dapagliflozin on symptoms and clinical events was not modified by baseline #Afib (Insight from the DELIVER)
jacc.org/doi/10.1016/j.… Muthu Vaduganathan scottdavidsolomon Sanjiv J. Shah, MD Carolyn Lam Gregg Fonarow MD Steve Greene #HeartFailure JACC Journals

Effects of #Canagliflozin on CV Outcomes According to Baseline #eGFR / #UACR

Integrated data analysis from the #CANVAS Program and the #CREDENCE trial

jacc.org/doi/10.1016/j.… #SGLT2i #HeartFailure JACC Journals #JACC

Learn more about #Atherosclerosis CVD from Drs. Naomi Hamburg, Steve Greene, Mikhail Kosiborod, and Jorge Plutzky at the 20th annual World Congress IR, DM & CVD this December. Save on registration today: wcir.org/registration

Boston U Chobanian & Avedisian School of Medicine Duke Clinical Research Institute Cardiometabolic Center Alliance Saint Luke's Brigham and Women's Hospital #meded #cme